Janssen Pharmaceutical Companies of Johnson & Johnson revealed ground-breaking results from a recent study, showing that wearable continuous electrocardiogram (ECG) monitoring patches were able to detect asymptomatic atrial fibrillation (AF) earlier and more efficiently than routine care. These results could lead to improvements in stroke prevention and comprehensive care.

Patients with AF have an increased risk of stroke and are associated with poorer stroke outcomes; almost 15% of all ischemic strokes are caused by atrial fibrillation and 60% of such strokes lead to permanent disability. While AF is a common and preventable cause of stroke, there are many barriers to detecting AF during routine care; namely, the irregularity or absence of symptoms in patients with AF.

Wearable devices are becoming increasingly popular, providing both the user and their primary care physician the ability to continuously monitor symptoms to detect even diseases that have irregular patterns of symptoms. The study by Janssen looked at 1,738 patients undergoing continuous ECG monitoring using a patch over four weeks. Results showed that “AF was newly diagnosed in 6.3% of patients wearing the ECG monitoring patch compared to 2.3% in the control group receiving routine care.” With a better detection rate, patients will be able to receive timely care for AF before the disease progresses to a severe form, leading to health complications and potentially ischemic stroke.

In addition to early treatment for managing AF, clinical trials have also shown the effectiveness of anticoagulation, a drug regularly used in stroke therapy, in patients with AF leading to a significant reduction in strokes. Including stroke therapy in the early to moderate stages of AF can maximise the prevention of stroke, protecting patients and reducing the burden to the healthcare system as a whole.

Improvements in the detection of AF will increase the patient population eligible for treatment through drugs or electrophysiology ablation procedures. As innovation in the electrophysiology field continues to refine ablation procedures to produce better patient outcomes more efficiently, GlobalData believes that the results of this study can lead to faster growth within the electrophysiology ablation market.


How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData